Bone health is the most clinically-regulated category in the peptide landscape. Unlike weight-loss or longevity peptides, where the story is a mix of FDA-approved agents and gray-market research compounds, every peptide in this guide is an FDA-approved prescription drug with decades of Phase 3 trial data, post-marketing surveillance, and formal labeling. There is no research-peptide tier here, and that shapes the editorial frame: this guide is strictly educational, aimed at helping readers understand how the approved peptide anabolics and antiresorptives fit into a broader osteoporosis treatment plan. It does not substitute for the judgment of an endocrinologist, rheumatologist, or primary care physician managing fracture risk.
The category divides cleanly into two mechanistic classes. Anabolic agents — teriparatide (Forteo) and abaloparatide (Tymlos) — actively stimulate new bone formation by pulsatile activation of the PTH1 receptor on osteoblasts. Antiresorptive agents — calcitonin, historically — reduce bone loss by inhibiting osteoclast activity. The modern first-line therapies for most patients with osteoporosis are non-peptide antiresorptives: bisphosphonates (alendronate, zoledronic acid) and the monoclonal antibody denosumab. Peptide anabolics are reserved for patients with severe osteoporosis, very high fracture risk, history of fracture on antiresorptive therapy, or glucocorticoid-induced osteoporosis.
This guide ranks three peptides. Both PTH-analog anabolics carry a boxed warning originating from rodent carcinogenicity studies and are limited to two years of cumulative lifetime use. Calcitonin is listed third because the FDA label was updated in 2013 noting a possible association with malignancy on long-term use, which has essentially removed it from first-line osteoporosis practice.
Teriparatide
Best for: First-line peptide anabolic for severe osteoporosis with the longest FDA track record
Teriparatide (Forteo, Bonsity) is a recombinant form of the first 34 amino acids of human parathyroid hormone and was the first anabolic osteoporosis therapy approved by the FDA, in 2002. The pivotal Fracture Prevention Trial (n=1,637) demonstrated a 65% reduction in vertebral fracture risk and a 53% reduction in non-vertebral fracture risk over 21 months. It increases lumbar spine BMD by roughly 9% and femoral neck BMD by roughly 3% over 18 months. It has the longest post-marketing safety record in the category, with 20+ years of clinical use and no osteosarcoma cases attributable to the drug reported in humans despite the boxed warning from rodent data.
Abaloparatide
Best for: Newer PTHrP analog with superior hip and femoral neck BMD gains vs teriparatide
Abaloparatide (Tymlos) is a synthetic 34-amino-acid PTHrP analog approved by the FDA in 2017. It is a more selective PTH1R agonist than teriparatide, with a stronger bias toward transient cAMP signaling that favors bone formation over resorption coupling. The pivotal ACTIVE trial (n=2,463) reported an 86% reduction in vertebral fracture risk and 43% reduction in non-vertebral fracture risk versus placebo over 18 months. In head-to-head comparison within ACTIVE, abaloparatide produced significantly greater BMD gains at the total hip and femoral neck than teriparatide. Same two-year lifetime use limit, same boxed-warning framework.
Calcitonin
Best for: Antiresorptive niche use in Paget's disease, acute hypercalcemia, or analgesic support
Calcitonin (Miacalcin, Fortical) is salmon calcitonin, a 32-amino-acid antiresorptive hormone approved by the FDA for postmenopausal osteoporosis, Paget's disease, and hypercalcemia. Unlike teriparatide and abaloparatide, it is antiresorptive rather than anabolic — it inhibits osteoclast activity via cAMP-coupled CTR signaling rather than driving new bone formation. The PROOF trial (5 years, 1,255 women) showed a 33% reduction in vertebral fracture risk with 200 IU/day intranasal dosing. It is no longer a first-line osteoporosis therapy: a 2013 FDA label update noted a possible increased risk of malignancy with long-term use, and bisphosphonates and denosumab are now preferred. Calcitonin retains a role in acute hypercalcemia and Paget's-associated bone pain (via its central analgesic effect).
Frequently asked questions
They are mechanistically similar — both are PTH1R agonists driving pulsatile anabolic bone formation — but not strictly interchangeable. Abaloparatide's more selective PTH1R signaling produced greater hip and femoral neck BMD gains in the ACTIVE trial's head-to-head comparison. Both carry a two-year lifetime use limit and the same boxed-warning framework. Choice between them is typically driven by prescriber preference, payer coverage, and injection device compatibility.
The two-year cumulative lifetime limit is derived from rat carcinogenicity studies that showed osteosarcoma at high doses with lifetime exposure. This triggered the FDA boxed warning and the duration restriction, which was applied to abaloparatide under the same framework. After 20+ years of clinical use, no osteosarcoma cases attributable to teriparatide have been reported in humans, but the label restriction remains. Treatment is typically followed by an antiresorptive (bisphosphonate or denosumab) to preserve the BMD gains.
Rarely as first-line. The 2013 FDA label update noting a possible association with malignancy on long-term use, combined with the availability of more effective alternatives (bisphosphonates, denosumab, teriparatide, abaloparatide), has essentially removed intranasal calcitonin from routine osteoporosis practice. It retains niche roles in acute hypercalcemia, Paget's disease, and situations where its central analgesic effect on bone pain is specifically desired.
Anabolic peptides (teriparatide, abaloparatide) can meaningfully increase bone mineral density rather than just slowing bone loss — that is the defining difference between anabolic and antiresorptive therapy. Lumbar spine BMD gains of 9% over 18 months on teriparatide are not trivial. That said, 'reversal' is too strong a frame: the gains must be preserved with follow-on antiresorptive therapy, and peptide anabolic treatment is constrained to two years lifetime.
BPC-157 and TB-500 are frequently discussed in the context of tendon, ligament, and soft-tissue healing, with primarily animal and in-vitro evidence. They are not FDA-approved, they are not indicated for osteoporosis, and there are no Phase 3 human fracture-reduction data supporting their use in bone disease. For osteoporosis specifically, the evidence-backed peptide options are the three FDA-approved drugs covered in this guide — not research peptides.